Laryngeal Neoplasms Clinical Trial
Official title:
A Multicenter, Randomized, Case-control Study of Unilateral vs Bilateral Selective Neck Dissection for Clinically Negative Neck of Supraglottic Laryngeal Carcinoma
Supraglottic laryngeal carcinoma patients with clinically negative neck (cN0) will be randomized divided into two groups. Patients in case group will undergo unilateral neck dissection (II-IV) while bilateral neck dissection (II-IV) in control group. Regional control rate is the primary endpoint and comparison will be made to see if unilateral dissection can get similar regional control as control group.
Some retrospective analysises showed the low local recurrence rate of patients who accepted
unilateral neck dissection with cN0 supraglottic laryngeal carcinoma. The aim of this study
is to see if unilateral dissection can get similar regional control as bilateral dissection.
308 patients with cN0 supraglottic laryngeal carcinoma will be enrolled in five centers of
northern China. Patients will be randomly assigned to 1: 1 ratio case group or control goup.
Patients in case group will undergo unilateral (laryngeal primary tumor affected side) neck
dissection (II-IV) while bilateral neck dissection (II-IV) in control group. And other
necessary standard treatments will be performed in both case group and control group.Allowed
by the patients, the investigators will obtain archived tumor specimens and 10ml peripheral
blood samples from the patients before surgery.
The patients will be followed-up every three months after surgery, until three years after
surgery or develop regional recurrence. During the follow-up procedure, radiological
evaluation will be performed. The primary end point is the patient's pathologically confirmed
regional lymph node recurrence. Patients with primary end point will enter the overall
survival follow-up stage. At the median follow-up time of two years, the investigators will
undergo a major regional control rate analysis, then, all patients will be followed-up to
five years postoperatively, and the overall survival analysis will be performed.
;
Status | Clinical Trial | Phase | |
---|---|---|---|
Not yet recruiting |
NCT05406024 -
Feasibility Study CORPPS
|
||
Terminated |
NCT00721539 -
Assessing the da Vinci® Robotic Surgical System for Surgery of the Upper Aerodigestive Tract
|
N/A | |
Completed |
NCT00534729 -
Organ Preservation: Weekly Carboplatin & Taxol w/Concurrent RT for Locally Advanced Laryngeal & Hypopharyngeal CA
|
N/A | |
Terminated |
NCT01216020 -
Cetuximab Plus Radiotherapy Versus Cisplatin Plus Radiotherapy in Locally Advanced Head and Neck Cancer
|
Phase 2 | |
Recruiting |
NCT06227039 -
Patient Augmented Reality and Vibratory Array Otorhinolaryngology Procedures
|
N/A | |
Not yet recruiting |
NCT06137378 -
European Larynx Organ Preservation Study (ELOS) [MK-3475-C44]
|
Phase 2 | |
Completed |
NCT00127465 -
Investigating the Impact of Tailored Reports on Anxiety Amongst Cancer Patients and Their Confidants
|
Phase 1/Phase 2 | |
Terminated |
NCT02633540 -
Investigation of Contralateral Arytenoid Sparing IMRT for T1a & T2a Larynx Cancer & Analysis of Post-treatment Laryngeal Function
|
Phase 2 | |
Terminated |
NCT00941135 -
Safety and Efficacy Study in Patients With Local Advanced Larynx/Hypolarynx Carcinoma Treated With TPF Induction Chemotherapy Followed by Hyperfractionated Radiotherapy With Cetuximab
|
Phase 2 | |
Recruiting |
NCT05768178 -
DETERMINE Trial Treatment Arm 05: Vemurafenib in Combination With Cobimetinib in Adult Patients With BRAF Positive Cancers.
|
Phase 2/Phase 3 | |
Completed |
NCT00721799 -
F-18 Fluorothymidine PET Imaging for Early Evaluation of Response to Therapy in Head & Neck Cancer Patients
|
Phase 2 | |
Enrolling by invitation |
NCT01171235 -
Study of Biomarker From Blood and Tissue of Head and Neck Carcinoma
|
N/A | |
Terminated |
NCT00965003 -
MRI Laryngeal Imaging With a Surface Coil
|
Early Phase 1 | |
Recruiting |
NCT02672904 -
KTP vs CO2 Laser for the Treatment of Laryngeal Carcinoma
|
N/A | |
Recruiting |
NCT04278638 -
IORT in Local Advanced Laryngocarcinoma
|
N/A | |
Completed |
NCT02430675 -
Irreversible Electroporation(IRE) For Unresectable Laryngeal Neoplasms
|
N/A | |
Completed |
NCT03585075 -
Characterization of the Autofluorescence of Healthy and Pathological Tissues of Vocal Cords
|
||
Completed |
NCT00576134 -
The Objective is to Respond to Patients' Needs in the Field of Larynx Replacement
|
Phase 1 | |
Completed |
NCT03010813 -
A Novel Robotic System for Single Port and Natural Orifice Transluminal Endoscopic Surgery
|
N/A | |
Recruiting |
NCT00396617 -
Voice Prosthesis Made in Porous Titanium After Total Laryngectomy or Pharyngolaryngectomy
|
Phase 1 |